If you've spent any time in healthcare services investing over the last 15 years, you've probably seen a version of the same story play out. A PE group acquires a platform of medical practices, promises physicians clinical autonomy and operational support, grows through acquisitions for 3 to 5 years, and then tries to exit at a higher multiple. Sometimes the exit happens and sometimes it doesn't. Either way, by the time the fund is winding down, the practices look different from what they were when the story started, and rarely in ways that benefited the people inside them.

The investors who did well in those deals got their money back with a return. The physicians, staff, and patients absorbed the cost of the model that produced it. The permanent hold structure rejects the assumptions that make the rollup model work the way it does, and the differences between the 2 run deeper than the hold period.

Why the PE Model Breaks in Healthcare

Private equity works in healthcare for the same reason it works anywhere else. Buy assets at a reasonable multiple, improve operations, and sell at a higher multiple. The math is straightforward and when it works it works well.

The problem is that the exit dependency creates a structural conflict with what makes medical practices valuable in the first place.

A medical practice generates revenue because patients trust the physicians who see them. That trust is built over years of consistent care, familiar faces, and a clinical environment where the patient feels known rather than processed. It doesn't appear on a balance sheet, but it's the most important asset the practice has, and it's fragile in ways that a manufacturing plant or a software company simply isn't.

PE platforms need to grow EBITDA to justify an exit valuation. Growing EBITDA in a medical practice means increasing volume, reducing costs, or both. Increasing volume means shorter appointment slots, more patients per day, and more pressure on the clinical team. Reducing costs means leaner staffing, standardized vendors, and rationalized overhead. Both of those levers pull directly against the patient trust that makes the practice worth acquiring in the first place.

The result is a predictable degradation pattern. Year 1 looks like the pitch deck. Year 2 the physicians start complaining about volume targets. Year 3 the best staff have turned over. Year 4 the patient satisfaction scores have moved. By year 5 the platform is trying to exit into a market that can see exactly what happened to the underlying businesses.

The exit dependency drives every one of those outcomes. When the entire model is built to manufacture a liquidity event within a fund cycle, every operational decision between acquisition and exit is shaped by that deadline, and the practices bear the cost of it.

What Permanent Hold Changes

A permanent hold vehicle has no exit to optimize for. That single structural difference changes every downstream incentive in the model.

Physicians in a permanent hold structure are managed toward sustainable clinical excellence that produces distributions for the next 20 years, which looks completely different from being managed toward a volume target that supports a sale process in year 5. The clinical team retains autonomy over patient care decisions because the platform's revenue depends on those decisions being right over decades, not being fast over quarters.

Staff retention carries a different weight when the holding period is indefinite. The technician who's been running the diagnostic suite for 12 years carries institutional knowledge that's worth more than the salary savings from replacing her with a lower-cost hire. A PE platform rationalizing headcount before an exit makes that trade because the cost savings show up in EBITDA and the knowledge loss shows up in someone else's problem after the sale. A permanent hold operator lives with the consequences of every staffing decision permanently, which changes how those decisions get made.

Patient relationships compound in a permanent hold model because the practice is built to keep them coming back for decades. The revenue in year 15 depends on the patient relationship built in year 1, and there's no exit event in between where the practice changes hands and the continuity resets. Patients feel the difference even when they can't articulate why, and the practices that retain the highest patient volumes over time are almost always the ones where ownership and clinical leadership have stayed consistent.

The investor's return in a permanent hold structure comes from operations as the practice generates cash. Distributions flow from real revenue, equity compounds as the platform grows, and neither of those things depends on finding a strategic buyer willing to pay a premium at the end of a fund cycle.

What You Look at Instead of Exits

PE funds are evaluated on IRR and MOIC. Clean numbers, benchmarks, and comparisons. Permanent hold platforms don't produce those numbers because there's no terminal event to calculate them against, and that's precisely the point.

What you look at instead is whether the business is actually healthy, measured by revenue stability year over year, physician retention, staff tenure, patient volume trends, and distribution consistency. These are the metrics that tell you whether the underlying asset is compounding or being hollowed out.

A PE platform can manufacture EBITDA for 3 years through the levers described above. The degradation doesn't show up until after the exit, which means it shows up in the next buyer's problem, not in the fund's return calculation. A permanent hold platform can't hide behind a transaction. The health of the business is the return, and it's visible in real time to everyone involved.

For an investor who has learned to read through PE healthcare pitches, that transparency is the feature that makes the model trustworthy.

Why This Matters Now Specifically

The ophthalmology succession wave is producing deal flow that PE platforms are largely ignoring because the individual practice sizes are below their threshold. That creates a window where a permanent hold operator can acquire practices at multiples that reflect the thin buyer market rather than the underlying quality of the asset.

As consolidation continues and the succession wave accelerates, that pricing environment will tighten. A permanent hold operator who builds a portfolio of practices in the tristate area over the next 3 years will own those assets at acquisition multiples that look increasingly attractive as the market catches up.

The PE model will eventually arrive in this segment at scale. When it does, it'll do what PE always does: acquire aggressively, optimize for an exit, and leave the underlying businesses changed by the process. The permanent hold platform that moves before that happens owns the best assets at the best prices and has years of operating history that demonstrates the model works before the competition shows up.

That advantage compounds with every quarter of operating data and every practice that stays physician-owned while the PE wave rolls through around it. If you've watched PE healthcare play out and are looking for a structure built differently at the foundation, we're open to the conversation.

This article is for general educational purposes and is not investment advice.

Verdira is a healthcare acquisition platform focused on ophthalmology practices, built around physician ownership, transparent structure, and no volume quotas. If you're evaluating permanent hold structures in healthcare and want to understand how we think about long-term practice ownership, we're open to thoughtful conversations.

Contact info@verdira.com | 307-381-3734 | verdira.com